[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367982-105":59,"doc-detail-367982-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","parpi-and-myeloid-neoplasms-the-italian-mito-mango-experience-based-on-a-multicentric-survey","PARPi and myeloid neoplasms - the Italian MITO-MaNGO experience based on a multicentric survey","","PARPi adoption in ovarian cancer has increased concern about PARPi-related myeloid neoplasms (PrMN). Therapy-related myeloid disorders, including myelodysplastic syndromes and acute myeloid leukemia, represent 10%–20% of cases, while broader PARPi use, longer survival, and aging may raise PrMN incidence. A 71-item survey across 17 Italian centers assessed PrMN in patients receiving PARPi outside clinical trials and quantified incidence, onset timing, response, and outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/parpi-and-myeloid-neoplasms-the-italian-mito-mango-experience-based-on-a-multicentric-survey/367982/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/parpi-and-myeloid-neoplasms-the-italian-mito-mango-experience-based-on-a-multicentric-survey/367982.png","ImageObject",300,407,{"name":92,"@type":93},"PakDamar76","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What concern does the study address regarding PARPi in ovarian cancer?","Question",{"text":112,"@type":113},"The study focuses on PARPi-related myeloid neoplasms (PrMN) as a rare but clinically relevant complication.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was PrMN incidence assessed across Italy?",{"text":117,"@type":113},"Incidence was evaluated across 17 Italian centers using a 71-item survey distributed to MITO and MaNGO centers, targeting patients treated with PARPi outside clinical trials.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show about PrMN frequency and timing?",{"text":121,"@type":113},"Among 2,320 patients, 56 developed myeloid neoplasms, with a median onset of 18.9 months; the risk varied by drug and increased with additional lines of therapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367982,1790698982,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962090893057,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","ORIGINAL ARTICLE  \nPARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric survey  \nM. Turinetto1 , 2 ∗, C. Marchetti3, G. Scandurra4 , 5, N. Colombo6 , 7, G. Cormio8 , 9, S. Cecere10, D. Pellegrini11, C. De Angelis12, C. Abeni13, M. C. Petrella14, A. Ferrero15, C. Camnasio16, 17, F. Villa18, S. Mammoliti19, M. Giordano20, G. Valabrega21, M. DeStefanis22, G. Cirigliano23, S. Boccia3, M. Distefano3, P. Chiusolo3, M. T. Perri3, V. Lombardo4 , 5, G. Caruso24 , 25,  \nV. Loizzi8, E. Coppola10, V. Barberi11, 26†, M. R. Lamia12, A. Fagotti3 & S. Pignata10  \n1Gynecological Oncology Unit, Humanitas San Pio X, Milan; 2University of Turin, Oncology Department, Turin; 3Fondazione Policlinico Universitario A. Gemelli, IRCCS, Department of Woman and Child and Public Health, Division of Gynecologic Oncology, Rome; 4Medical Oncology Unit, Cannizzaro Hospital, Catania; 5Faculty of Medicine, Kore University of Enna, Enna; 6Gynecology Program, European Institute of Oncology, IRCCS, Milan; 7Department of Medicine and Surgery, University of Milan-Bicocca, Milan; 8Azienda Ospedaliera Universitaria “Policlinico di Bari” - Clinica di Ginecologia e Ostetricia, Bari; 9Gynecologic Oncology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari; 10Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples; 11Medical Oncology, IRCCS Regina Elena National Cancer Institute, Rome; 12Department of Clinical Medicine and Surgery, University Federico II, Naples; 13Department of Clinical Oncology, Fondazione Poliambulanza, Brescia; 14Oncologia Medica Ginecologica, Azienda Universitaria Ospedaliera Careggi, Florence; 15Department of Gynecology and Obstetrics, Mauriziano Hospital, University of Turin, Turin; 16Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia; 17Unit of Obstetrics and Gynecology, IRCCS San Matteo Foundation, Pavia; 18Oncology Unit, Department of Oncology, Alessandro Manzoni Hospital, ASST Lecco, Lecco; 19IRCCS Ospedale Policlinico San Martino, Genova; 20S.C. di Oncologia, Azienda Ospedaliera S. Anna, Como; 21Department of Oncology, University of Turin, Ordine Mauriziano Hospital, Turin; 22Department of Obstetrics and Gynecology, Azienda Ospdaliera Santa Croce e Carle, Cuneo; 23Oncology Department, Ospedale di San Luca, Lucca; 24Department of Gynecology, European Institute of Oncology, IEO, IRCCS, Milan; 25Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy; 26Breast Cancer Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain  \nAvailable online 18 November 2025  \nIntroduction: The introduction of poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer has raised increasing concerns about PARPi-related myeloid neoplasms (PrMN) . Therapy-related neoplasms, including myelodysplastic syndromes and acute myeloid leukemia, account for 10%-20% of cases. Expanding PARPi indications, longer survival, and aging populations may contribute to rising PrMN incidence. Randomized clinical trials and real-world analyses show a significant risk increase, but data on individual PARPi, treatment lines, and prior therapies are limited.  \nMethods: We evaluated PrMN incidence across 17 Italian centers using a 71-item survey distributed to MITO (Multicenter Italian Trials on Ovarian cancer) and MaNGO (Mario Negri Gynecologic Oncology) centers, focusing on patients treated with PARPi outside clinical trials.  \nResults: Of 2320 patients (1254 BRCA-mutated), 56 (2 .55%) developed MN: 35 myelodysplastic syndromes and 21 acute myeloid leukemia (2 patients had both, counted once) . Among them, 31 had BRCA mutations (2 .5%) . Incidence by drug was: olaparib 2.5%, niraparib 2%, and rucaparib 3.4% . An unclear correlation emerged between treatment duration and PrMN risk, with a median onset of 18.9 months. Risk increased with additional therapy lines: 0.52%(first), 4. 2%(second), 1.8%(third), 10.8%(fourth), and 12. 2","cbCaii55QoENnQZV","https://ap.wps.com/l/cbCaii55QoENnQZV","pdf",408673,"English","# Introduction\n# Methods\n# Results\n# Conclusions\n# Correspondence","[{\"question\":\"What concern does the study address regarding PARPi in ovarian cancer?\",\"answer\":\"The study focuses on PARPi-related myeloid neoplasms (PrMN) as a rare but clinically relevant complication.\"},{\"question\":\"How was PrMN incidence assessed across Italy?\",\"answer\":\"Incidence was evaluated across 17 Italian centers using a 71-item survey distributed to MITO and MaNGO centers, targeting patients treated with PARPi outside clinical trials.\"},{\"question\":\"What did the results show about PrMN frequency and timing?\",\"answer\":\"Among 2,320 patients, 56 developed myeloid neoplasms, with a median onset of 18.9 months; the risk varied by drug and increased with additional lines of therapy.\"}]","PARPi and myeloid neoplasms - the Italian MITO-MaNGO experience based on a multicentric survey | PDF",1790174178,15,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bcc714af3d5ec9f1c785f861d02a60f3.webp",983,1269,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d1089a263f92602738d9365eff912d55.webp",982,1268,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0dd084d6b8e6bf8fb2485b72ab2adc4.webp",981,1266,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5649c4ae5beeba89c0680774a7dca77b.webp",980,1265]